1. COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) – PHASE II TRIAL. (12th June 2019) Authors: Jain, P.; Romaguera, J.; Nomie, K.; Zhang, S.; Wang, L.; Oriabure, O.; Wagner‐Bartak, N.; Zhang, L.; Hagemeister, F.; Samaniego, F.; Westin, J.; Ju Lee, H.; Nastoupil, L.; Iyer, S.; Parmar, S.; Ok, C.; Kanagal‐Shamanna, R.; Chen, W.; Thirumurthi, S.; Santos, D. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. IBRUTINIB WITH RITUXIMAB (IR) AND SHORT COURSE R‐HYPERCVAD/MTX IS VERY EFFICACIOUS IN PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE CELL LYMPHOMA (MCL). (12th June 2019) Authors: Wang, M.; Jain, P.; Zhang, S.; Nomie, K.; Wang, L.; Oriabure, O.; Nogueras Gonzales, G.; Zhang, L.; Wagner‐Bartak, N.; Hagemeister, F.; Samaniego, F.; Westin, J.; Lee, H.J.; Nastoupil, L.; Ok, C.; Kanagal‐Shamanna, R.; Chen, W.; Thirumurthi, S.; Santos, D.; Badillo, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO. (June 2017) Authors: Wang, M.L.; Lee, H.; Thirumurthi, S.; Chuang, H.; Hagemeister, F.; Westin, J.; Fayad, L.; Samaniego, F.; Turturro, F.; Chen, W.; Oriabure, O.; Feng, L.; Zhou, S.; Huang, S.; Li, S.; Zhang, L.; Badillo, M.; Wu, L.; Ahmed, M.; Yan, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Improved outcome for patients with relapsed/refractory mantle cell lymphoma (MCL) who stop ibrutinib +/− rituximab for reasons other than progression of disease. (June 2017) Authors: Chen, W.; Zeng, D.; Desai, A.; Badillo, M.; Feng, L.; Yan, F.; Nomie, K.; Ping, L.; Ye, H.; Liang, Y.; Lee, H.; Oki, Y.; Romaguera, J.; Wang, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 360 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PP.24.16: PERIPHERAL, CENTRAL NON INVASIVE HEMODYNAMICS AND ARTERIAL SITFFNESS IN EARLY PUERPERIUM NORMAL AND COMPLICATED HYPERTENSIVE DISEASE PREGNANCY. (June 2015) Authors: Lopez-Rivera, J.; Cedeño-Buitrago, M.; Lopez-Saavedra, J.; Scrocchi, S.; Badillo, M. Journal: Journal of hypertension Issue: Volume 33(2015)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗